Lee Anton, MD
Internal Medicine · North Port, FLNPI 1942202478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,767 and has fallen 64.6% since, to $626 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$818
- AbbVie$641
- Novo Nordisk$484
- Boston Scientific$461
- Pfizer$336
- Amgen$333
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,117100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 47 | $818 |
| AbbVie(2 entities) | 33 | $641 |
| Novo Nordisk | 29 | $484 |
| Boston Scientific | 7 | $461 |
| Pfizer | 19 | $336 |
| Amgen | 21 | $333 |
| GSK | 22 | $323 |
| AstraZeneca | 12 | $215 |
| Merck | 16 | $187 |
| Corcept Therapeutics | 7 | $155 |
| Boehringer Ingelheim | 7 | $139 |
| E.r. Squibb & Sons, L.L.C. | 7 | $134 |
| Xeris Pharmaceuticals, Inc. | 5 | $105 |
| Abbott | 5 | $96 |
| Novartis | 6 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $81 |
| Amarin Pharma, Inc. | 5 | $69 |
| Bayer | 2 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Radius Health, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Exact Sciences | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| BETA Bionics, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$144
- WATCHMAN FLX$144
- MOUNJARO$120
How this compares
$5,123 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 154 | $214,500 |
| EliquisApixaban | 156 | $206,480 |
| FarxigaDapagliflozin Propanediol | 122 | $159,851 |
| JardianceEmpagliflozin | 98 | $118,607 |
| OzempicSemaglutide | 91 | $106,170 |
| Repatha SureclickEvolocumab | 107 | $86,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $85,790 |
| XareltoRivaroxaban | 34 | $42,251 |
| JanuviaSitagliptin Phosphate | 35 | $37,661 |
| XifaxanRifaximin | 12 | $29,631 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $24,944 |
| LinzessLinaclotide | 18 | $19,227 |
| RexultiBrexpiprazole | 12 | $17,134 |
| VascepaIcosapent Ethyl | 23 | $16,215 |
| Icosapent Ethyl | 17 | $9,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $818 | $214,500154 claims |
| PfizerEliquis | $336 | $206,480156 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $215 | $189,636168 claims |
| Boehringer IngelheimJardiance | $139 | $118,60798 claims |
| Novo NordiskOzempic | $484 | $106,17091 claims |
| GSKTrelegy Ellipta | $323 | $85,790100 claims |
| Johnson & JohnsonXarelto | $19 | $42,25134 claims |
| MerckJanuvia | $187 | $37,66135 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $81 | $29,63112 claims |
| AbbVieLinzess, Synthroid | $641 | $23,28872 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $8,47217 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $5,220672 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in North Port
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.